Nexalin Therapy as a Viable Adjunctive Treatment for Substance Use Disorders

Running, not enrolling · Not applicable · Has a placebo group

Conditions studied: Depression, Anxiety, Insomnia, Substance Abuse

In brief

The purpose of this research study is to determine whether Nexalin Trans-cranial Electrical Stimulation (TES) is a viable adjunctive treatment of substance use treatments.

Key facts

Study ID

NCT03540745

Run by

University of Arizona

People needed

14

Starts

2018-06-11

Expected to finish

2019-11-01

Last updated by the study team

2018-10-11

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be able to provide informed consent, assessed by the study clinician
• Be able to speak, read and write fluently in English, assessed by the study clinician
• Be committed to completion of the study. The subject will need to attest to availability for 10 to 15 treatments over a 5 to 8 day period for the treatment protocol.
• Be adults over age 18 and under age 65
• Be actively receiving substance use treatment for a substance use disorder

You may not qualify if…

• Pregnant or at risk of becoming pregnant
• Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, might confound the interpretation of the study results, or put the person at undue risk

Where it is running

• Carrier Clinic — Belle Mead, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.